Analysis of the Impact of Rosuvastatin on Bacterial Mevalonate Production Using a UPLC-Mass Spectrometry Approach

Current Microbiology

Volumn 73, Issue 1, 2016, Pages 1-8

  Nolan, J A ^a,b   Kinsella, M ^b,c   Hill, C ^a,b   Joyce, S A ^a,b   Gahan, C G M ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

^c South East Technological University   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; ROSUVASTATIN;

ARTICLE; BACTERIAL CELL; BACTERIAL GROWTH; BACTERIUM CULTURE; CONTROLLED STUDY; DOSE RESPONSE; EFFECTIVE CONCENTRATION; ENTEROCOCCUS FAECIUM; GROWTH INHIBITION; LISTERIA MONOCYTOGENES; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; SUPERNATANT; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; CHEMISTRY; DRUG EFFECTS; EVALUATION STUDY; GROWTH, DEVELOPMENT AND AGING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; PROCEDURES;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENTEROCOCCUS FAECIUM; LISTERIA MONOCYTOGENES; MASS SPECTROMETRY; MEVALONIC ACID; ROSUVASTATIN CALCIUM; STAPHYLOCOCCUS AUREUS;

EID: 84960467623     PISSN: 03438651     EISSN: 14320991     Source Type: Journal    
DOI: 10.1007/s00284-016-1014-z     Document Type: Article

References (20)

1. Bergman P, Linde C, Putsep K, Pohanka A, Normark S, Henriques-Normark B, Andersson J, Bjorkhem-Bergman L (2011) Studies on the antibacterial effects of statins–in vitro and in vivo. PLoS One 6(8):e24394
2. Das R, Pal TK (2014) Validation of liquid chromatography-tandem mass spectrometry for mevalonate in human plasma: incompetent effects between treated atorvastatin & its combination with olmesartan in cardiovascular patients. J Young Pharm 6(2):50–57
3. Dueber JE, Wu GC, Malmirchegini GR, Moon TS, Petzold CJ, Ullal AV, Prather KL, Keasling JD (2009) Synthetic protein scaffolds provide modular control over metabolic flux. Nat Biotechnol 27(8):753–759
4. Emani S, Gunjiganur GV, Mehta DS (2014) Determination of the antibacterial activity of simvastatin against periodontal pathogens, Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans: an in vitro study. Contemp Clin Dent 5(3):377–382
5. Hennessy E, Mooij MJ, Legendre C, Reen FJ, O’Callaghan J, Adams C, O’Gara F (2013) Statins inhibit in vitro virulence phenotypes of Pseudomonas aeruginosa. J Antibiot 66(2):99–101
6. Hennessy E, O’Callaghan J, Mooij MJ, Legendre C, Camacho-Vanegas O, Camacho SC, Adams C, Martignetti JA, O’Gara F (2014) The impact of simvastatin on pulmonary effectors of Pseudomonas aeruginosa infection. PLoS One 9(7):e102200
7. Heuston S, Begley M, Davey MS, Eberl M, Casey PG, Hill C, Gahan CG (2012) HmgR, a key enzyme in the mevalonate pathway for isoprenoid biosynthesis, is essential for growth of Listeria monocytogenes EGDe. Microbiology 158(Pt 7):1684–1693
8. Heuston S, Begley M, Gahan CG, Hill C (2012) Isoprenoid biosynthesis in bacterial pathogens. Microbiology 158(Pt 6):1389–1401
9. Istvan ES (2002) Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Am Heart J 144(6 Suppl):S27–S32
10. Jerwood S, Cohen J (2008) Unexpected antimicrobial effect of statins. J Antimicrob Chemother 61(2):362–364
11. Johansen ME, Green LA, Sen A, Kircher S, Richardson CR (2014) Cardiovascular risk and statin use in the United States. Ann Fam Med 12(3):215–223
12. Lange BM, Rujan T, Martin W, Croteau R (2000) Isoprenoid biosynthesis: the evolution of two ancient and distinct pathways across genomes. Proc Natl Acad Sci USA 97(24):13172–13177
13. Lombard J, Moreira D (2011) Origins and early evolution of the mevalonate pathway of isoprenoid biosynthesis in the three domains of life. Mol Biol Evol 28(1):87–99
14. Masadeh M, Mhaidat N, Alzoubi K, Al-Azzam S, Alnasser Z (2012) Antibacterial activity of statins: a comparative study of atorvastatin, simvastatin, and rosuvastatin. Ann Clin Microbiol Antimicrob 11:13
15. Matsuoka T, Ueda S, Matsumoto H, Kawakami M (2012) An ultrasensitive enzymatic method for measuring mevalonic acid in serum. J Lipid Res 53(9):1987–1992
16. Motzkus-Feagans CA, Pakyz A, Polk R, Gambassi G, Lapane KL (2012) Statin use and the risk of Clostridium difficile in academic medical centres. Gut 61(11):1538–1542
17. Park SW, Choi AR, Lee HJ, Chung H, Park JC, Shin SK, Lee SK, Lee YC, Kim JE, Lee H (2013) The effects of statins on the clinical outcomes of Clostridium difficile infection in hospitalised patients. Aliment Pharmacol Ther 38(6):619–627
18. Tabernero L, Rodwell VW, Stauffacher CV (2003) Crystal structure of a statin bound to a class II hydroxymethylglutaryl-CoA reductase. J Biol Chem 278(22):19933–19938
19. Tauch A, Bischoff N, Puhler A, Kalinowski J (2004) Comparative genomics identified two conserved DNA modules in a corynebacterial plasmid family present in clinical isolates of the opportunistic human pathogen Corynebacterium jeikeium. Plasmid 52(2):102–118
20. Waldron J, Webster C (2011) Liquid chromatography-tandem mass spectrometry method for the measurement of serum mevalonic acid: a novel marker of hydroxymethylglutaryl coenzyme A reductase inhibition by statins. Ann Clin Biochem 48(Pt 3):223–232